

Nick Powell

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8727793/nick-powell-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40
papers

1,409
citations

16
h-index

37
g-index

43
ext. papers

2,075
ext. citations

13.8
avg, IF

4.85
L-index

#	Paper	IF	Citations
40	The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells. <i>Immunity</i> , 2012 , 37, 674-84	32.3	244
39	The mucosal immune system: master regulator of bidirectional gut-brain communications. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017 , 14, 143-159	24.2	175
38	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. <i>Gut</i> , 2020 , 69, 984-990	19.2	159
37	Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease. <i>Gut</i> , 2016 , 65, 584-94	19.2	120
36	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. <i>Gut</i> , 2021 , 70, 1884-1893	19.2	93
35	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. <i>Gut</i> , 2021 , 70, 865-875	19.2	76
34	The unusual suspects--innate lymphoid cells as novel therapeutic targets in IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015 , 12, 271-83	24.2	62
33	Human retinoic acid-regulated CD161 regulatory T cells support wound repair in intestinal mucosa. <i>Nature Immunology</i> , 2018 , 19, 1403-1414	19.1	58
32	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 222-234	24.2	54
31	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 218-224	18.8	54
30	Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation. <i>Gastroenterology</i> , 2015 , 149, 456-67.e15	13.3	50
29	Interrogating host immunity to predict treatment response in inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 9-20	24.2	46
28	Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells. <i>Gut</i> , 2020 , 69, 578-590	19.2	36
27	Group 3 ILCs: Peacekeepers or Troublemakers? What's Your Gut Telling You?!. <i>Frontiers in Immunology</i> , 2019 , 10, 676	8.4	22
26	Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. <i>Rheumatology</i> , 2019 , 58, vii17-vii28	3.9	19
25	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. <i>Gut</i> , 2020 , 69, 1769-1777	19.2	18
24	Advances in mesenchymal stromal cell therapy in the management of Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 141-153	4.2	14

23	Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients. <i>Journal of Crohns and Colitis</i> , 2021 ,	1.5	13
22	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 271-281	18.8	11
21	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	10
20	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 679-697	18.8	9
19	Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1432-1452	6.1	9
18	Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2017 , 10, 57-66	3.1	8
17	Topical beclometasone dipropionate in the management of immune checkpoint inhibitor-induced microscopic colitis. <i>BMJ Case Reports</i> , 2019 , 12,	0.9	6
16	Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 ,	6.1	5
15	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines		5
14	SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 528-529	18.8	4
13	Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 987-988	18.8	3
12	Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients		3
11	Cognitive Impairment in Adult Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2021 , 62, 387-403		3
10	T-Bet Controls Cellularity of Intestinal Group 3 Innate Lymphoid Cells. <i>Frontiers in Immunology</i> , 2020 , 11, 623324	8.4	3
9	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.. <i>Nature Communications</i> , 2022 , 13, 1379	17.4	3
8	Out of Sight, Out of Mind: The Limitations of the Hospital Anxiety and Depression Scale in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, e100	4.5	2
7	PTU-009 Upper gastrointestinal inflammation in patients with immune-checkpoint inhibitor induced diarrhoea 2018 ,		2
6	Characterizing Innate Lymphoid Cell Phenotype and Function in Human Inflammatory Bowel Disease. <i>Methods in Molecular Biology</i> , 2020 , 2121, 199-211	1.4	2

5	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in infliximab- and vedolizumab-treated patients		1
4	Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab 2021 , 9,		1
3	Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation?. <i>Gut</i> , 2020 , 69, 609-610	19.2	1
2	Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity.. <i>Gut</i> , 2022 ,	19.2	1
1	SARS-CoV-2 vaccination for patients with inflammatory bowel disease - AuthorsUreply. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 523-524	18.8	0